APRINOIA Therapeutics

1:15 PM - 1:30 PM, Tuesday, June 4,2019 ・ Theater 2
APRINOIA discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life. Our goal is to create novel products to meet critical patient needs, including novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and novel therapies to improve the treatment of human neurological conditions.
Speaker
photo
CEO
APRINOIA Therapeutics